Growth Metrics

Novartis Ag (NVS) Enterprise Value Growth (1y) (2010 - 2025)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 -4.54%
Sep 30, 2025 275.83%
Jun 30, 2025 15.56%
Dec 31, 2024 84.94%
Sep 30, 2024 62.73%
Jun 30, 2024 33.68%
Dec 31, 2023 23.90%
Sep 30, 2023 -6,340.00%
Jun 30, 2023 -236.23%
Mar 31, 2023 101.37%
Dec 31, 2022 33.07%
Sep 30, 2022 -106.41%
Jun 30, 2022 29.56%
Mar 31, 2022 -1,116.67%
Dec 31, 2021 -143.66%
Sep 30, 2021 2,700.00%
Jun 30, 2021 14.93%
Mar 31, 2021 92.41%
Dec 31, 2020 -4.16%
Sep 30, 2020 -108.11%
Jun 30, 2020 55.17%
Mar 31, 2020 81.24%
Dec 31, 2019 27.38%
Sep 30, 2019 -8.64%
Jun 30, 2019 -50.36%
Mar 31, 2019 -14,133.33%
Dec 31, 2018 -61.10%
Sep 30, 2018 -59.30%
Jun 30, 2018 -19.18%
Mar 31, 2018 -97.30%
Dec 31, 2017 -30.68%
Sep 30, 2017 25.16%
Jun 30, 2017 -107.83%
Mar 31, 2017 -99.94%
Dec 31, 2016 -51.02%
Sep 30, 2016 100.12%
Jun 30, 2016 4,700,000,003,700.00%
Mar 31, 2016 282,352,941,076.47%
Dec 31, 2015 98.65%
Sep 30, 2015 -178,366,216,316.22%
Jun 30, 2015 -93.33%
Mar 31, 2015 151.85%
Dec 31, 2014 -304,213,675,313.68%
Sep 30, 2014 -43.94%
Jun 30, 2014 -77.78%
Mar 31, 2014 -77.31%
Sep 30, 2013 7.32%
Jun 30, 2013 21.62%
Mar 31, 2013 440.91%
Sep 30, 2012 26.80%
Jun 30, 2012 404.55%
Mar 31, 2012 -56.86%
Dec 31, 2011 -45.14%
Sep 30, 2011 22.78%
Jun 30, 2011 10.00%
Mar 31, 2011 240.00%
Dec 31, 2010 100.00%
Sep 30, 2010 119.44%
Jun 30, 2010 122.22%
Mar 31, 2010 15.38%